glimepiride has been researched along with Hypertension in 8 studies
glimepiride: structure given in first source
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add-on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride)." | 8.12 | Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study. ( Bhat, MH; Masoodi, SR; Mir, SA; Najar, IA; Patyar, RR; Patyar, S, 2022) |
| "In type 2 diabetic patients, the vasodilating response to forearm ischemia was the same whether patients were treated with diet treatment alone or with glibenclamide or glimepiride at blood glucose-lowering equipotent closes." | 5.09 | Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. ( Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P, 2001) |
| "The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add-on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride)." | 4.12 | Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study. ( Bhat, MH; Masoodi, SR; Mir, SA; Najar, IA; Patyar, RR; Patyar, S, 2022) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | 3.11 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| "With single doses, there was a clear dose-response relationship for the reduction in AUC, with a statistically significant difference only between placebo (mean 1981, 95% confidence intervals (CI) 1883-2078) and 2 mg glimepiride (mean 1763, 95% CI 1665-1861)." | 2.70 | The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. ( Lindblad, U; Lindwall, K; Melander, A; Ranstam, J; Sjöstrand, A, 2001) |
| "Her treatment was metformin 850 mg every 12 hours and glimepiride 4 mg every 24 hours." | 1.40 | How to prevent and treat pharmacological hypoglycemias. ( Mezquita Raya, P; Reyes García, R, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nathan, DM | 1 |
| Lachin, JM | 1 |
| Bebu, I | 1 |
| Burch, HB | 1 |
| Buse, JB | 1 |
| Cherrington, AL | 1 |
| Fortmann, SP | 1 |
| Green, JB | 1 |
| Kahn, SE | 1 |
| Kirkman, MS | 1 |
| Krause-Steinrauf, H | 1 |
| Larkin, ME | 1 |
| Phillips, LS | 1 |
| Pop-Busui, R | 1 |
| Steffes, M | 1 |
| Tiktin, M | 1 |
| Tripputi, M | 1 |
| Wexler, DJ | 1 |
| Younes, N | 1 |
| Najar, IA | 3 |
| Masoodi, SR | 3 |
| Mir, SA | 3 |
| Bhat, MH | 3 |
| Patyar, RR | 3 |
| Patyar, S | 3 |
| Wang, B | 1 |
| Zhong, J | 1 |
| Lin, H | 1 |
| Zhao, Z | 1 |
| Yan, Z | 1 |
| He, H | 1 |
| Ni, Y | 1 |
| Liu, D | 1 |
| Zhu, Z | 1 |
| Hung, YC | 1 |
| Lin, CC | 1 |
| Wang, TY | 1 |
| Chang, MP | 1 |
| Sung, FC | 1 |
| Chen, CC | 1 |
| Reyes García, R | 1 |
| Mezquita Raya, P | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Spallarossa, P | 1 |
| Schiavo, M | 1 |
| Rossettin, P | 1 |
| Cordone, S | 1 |
| Olivotti, L | 1 |
| Cordera, R | 1 |
| Brunelli, C | 1 |
| Lindblad, U | 1 |
| Lindwall, K | 1 |
| Sjöstrand, A | 1 |
| Ranstam, J | 1 |
| Melander, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for glimepiride and Hypertension
| Article | Year |
|---|---|
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Topics: Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2013 |
3 trials available for glimepiride and Hypertension
| Article | Year |
|---|---|
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Co | 2022 |
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic; | 2001 |
The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose.
Topics: Blood Glucose; Body Constitution; Body Mass Index; Cholesterol; Dose-Response Relationship, Drug; Do | 2001 |
4 other studies available for glimepiride and Hypertension
| Article | Year |
|---|---|
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H | 2022 |
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Coronary Di | 2013 |
How to prevent and treat pharmacological hypoglycemias.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperc | 2014 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |